Biotech

#Biotech #Financing #mRNA #Seed funding

Biotech raises a €31.5m seed round to develop mRNA therapeutics

SRTD Biotech has announced the successful completion of an oversubscribed €31.5 million seed financing round.   The financing was led by Mérieux Equity Partners, with NRW.BANK and Boehringer Ingelheim Venture Fund joining the syndicate as co-leads. Lilly Ventures, HTGF, and the Freiburg-based family Office Anobis Asset also participated… Read More

#Business & Investment #News #Start-up Zone

Berlin cityscape
#BioInnovation Institute #Biotech #Cardiometabolic diseases #Drug discovery #Europe

German hubs selected for BII cardiometabolic research initiative

BioInnovation Institute (BII) has selected Munich and Berlin as the locations for its German activities under the CardioMetabolic Bridge (CMB) initiative.   The expansion marks another important milestone in BII’s ambition to build a connected European innovation ecosystem dedicated to accelerating the development of new treatments for cardiometabolic… Read More

#News

#Antibody drug conjugate (ADC) #Biotech #Investment #Oncology #Women in STEM

Women in biopharma: Valerie Vanhooren, Ona Therapeutics 

In this series, DDW speaks to women in leading positions across biopharma about the work they’re doing and their experiences within the industry. Here, we speak to Valerie Vanhooren, Co-Founder & CEO, at Ona Therapeutics, about approaches in oncology, the remaining potential in the ADC field, and… Read More

#Exclusive Content

#Awards #Biopharma #Biotech #BioUK #Life sciences

BioUK Awards 2026 celebrate innovation in UK life sciences

BioUK has announced the winners of the 18th annual BioUK Awards following a ceremony hosted at the Royal Lancaster Hotel, London.   The biopharma and biotech winners of the 2026 BioUK Awards included:  The Best Start-Up Biotech Company Award, sponsored by Milton Park, was awarded to… Read More

#News

#Biotech #Drug discovery #Funding #Investment

3 key takes from Optimum’s Investor Conference

DDW Editor Reece Armstrong offers three key takeaways from Optimum’s Annual Healthcare Investor Conference.  AI is still dominating the conversation AI was an obvious talking point throughout the conference, with its application in both investing and in drug discovery and development being major points of discussion. As someone who regularly… Read More

#Exclusive Content

Basel map
#Academic #Biotech #Drug development #Drug discovery #Life sciences

How the right environment accelerates biotech innovation

Christof Klöpper, CEO of Basel Area Business and Innovation, discusses how ecoystems for biotech can advance innovation and how the Basel area is an example of an impressive concentration of talent.  A decade ago, the typical formula for biotech locations went something like this: emerge from an academic institution or… Read More

#Exclusive Content

Novartis head office
#Biotech #Mergers and acquisitions #Myricx Bio #Novartis

Novartis acquires ADC developer Myricx Bio 

UK biotech Myricx Bio has reached an agreement to be acquired by Novartis for up to $1.5 billion.  The companies say the acquisition advances antibody-drug conjugate (ADC) innovation by bringing together the strengths of Novartis in oncology with Myricx Bio’s two lead ADC assets and next-generation first-in-class N-myristoyltransferase inhibitor (NMTi) payload platform, having potential… Read More

#Business & Investment #News

#Biotech #Exonate #Ophthalmology

Eye disease specialist Exonate appoints Hellebø as CEO 

Biotechnology company Exonate has appointed Olav Hellebø as Chief Executive Officer.  Exonate, which specialises in small-molecule therapeutics for patients with retinal vascular diseases, says Hellebø will lead the company as it strengthens its executive team and advances toward key clinical and corporate milestones, including initiating a Phase IIb clinical trial of… Read More

#News

#Biotech #Broken String Biosciences #Gene editing

Broken String Biosciences appoints Bruce Eaton to board 

Broken String Biosciences has appointed Bruce Eaton as Chairman of the Board.  The appointment from the biotechnology company allows it to drive the global commercialisation of its INDUCE-seq platform, which it says can provide rapid, unbiased, genome-wide measurement of on- and off-target DNA breaks directly in customers’ own… Read More

#News

Scientist using a laptop
#Biotech #CDMO #Clinical trial

Biotech reliance on large CDMOs could cause overruns of 40% 

Overreliance of biotechs on large CDMOs could cause overruns of up to 40%, an industry expert has warned.  Madhav Bhutada, Director of Shilpa Biologicals, urged biotechs to take a broader and earlier approach to CDMO selection as funding conditions improve across the sector.   Bhutada said many emerging biopharma innovators –… Read More

#News

#Biotech #Infinitopes

Infinitopes appoints CSO to advance immuno-oncology pipeline 

Biotechnology company Infinitopes has appointed Jo Brewer as Chief Scientific Officer (CSO) and interim Chief Operating Officer (COO).  The company hopes Brewer’s appointment will allow it to advance a therapeutic pipeline of cancer therapies from clinical to commercialisation.  With 20 years of experience in advancing therapies from… Read More

#News

#Biotech #Cell and gene therapy #Cell and Gene Therapy Catapult #UK

How strong is the UK’s advanced therapy sector?  

DDW Editor Reece Armstrong speaks to Jacqueline Barry, Chief Clinical Officer at Cell and Gene Therapy Catapult, about the UK’s strong position in advanced therapies and what the challenges are for making the country competitive within pharma.   RA: Why does the UK have a strong in position in clinical… Read More

#Exclusive Content

#Biotech #Investment #T cell engagers

Cytospire raises £61m to advance T cell engager pipeline 

UK biotech company Cytospire Therapeutics has closed a £61 million ($83 million) Series A financing round to advance T cell engagers, 4BIO Capital has announced.  The venture capital firm led the financing round, with proceeds allowing Cytospire to advance its pipeline of first-in-class pan-gamma delta T cell engagers. The company’s lead programme,… Read More

#Business & Investment #News